3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
102
Lung Neoplasms
39
Neoplasms
11
Neoplasm Metastasis
11
Colorectal Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Pancreatic Neoplasms
6
Mesothelioma, Malignant
5
Mesothelioma
5
Carcinoma
5
Ovarian Neoplasms
4
Meningeal Carcinomatosis
4
Melanoma
4
Colonic Neoplasms
4
Advanced Solid Tumors
4
Rectal Neoplasms
3
Adenocarcinoma of Lung
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Non-squamous Non-small Cell Lung Cancer
2
Neoplasms by Site
2
Lung Diseases
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Pancreatic Ductal
2
Carcinoma, Bronchogenic
2
Bronchial Neoplasms
2
Brain Neoplasms
2
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
cabozantinib
5
Everolimus
5
pembrolizumab
4
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
tivozanib
1
surufatinib
1
repotrectinib
1
peposertib
1
pazopanib
1
entrectinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Pemetrexed
×
90 days
×
Clear all
No trials found.